PMDA — authorised 25 August 2021
- Marketing authorisation holder: NIPPON SHINYAKU Co., Ltd
- Status: approved
PMDA authorised Uptravi on 25 August 2021
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. PMDA authorised it on 25 August 2021; PMDA has authorised it.
NIPPON SHINYAKU Co., Ltd holds the Japanese marketing authorisation.